ArticleMediators of inflammation2015
Elevated Plasma IL-38 Concentrations in Patients with Acute ST-Segment Elevation Myocardial Infarction and Their Dynamics after Reperfusion Treatment.
Article in Mediators of inflammation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Immunobiological Properties and Clinical Applications of Interleukin-38 for Immune-Mediated Disorders: A Systematic Review Study.International journal of molecular sciences · 2021Pooled it
- Interleukin-38 Ameliorates Atherosclerosis by Inhibiting Macrophage M1-like Polarization and Apoptosis.Biomolecules · 2025Article
- Interleukin-38 as a potential diagnostic biomarker for heart failure.Biomarkers in medicine · 2025Article
- The amelioration effect of antidiabetic agents on cytokine expression in patients with type 2 diabetes mellitus.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- Emerging functions and therapeutic targets of IL-38 in central nervous system diseases.CNS neuroscience & therapeutics · 2024Review
- Evaluation of IL-38, a Newly-introduced Cytokine, in Sera of Vitiligo Patients and Its Relation to Clinical Features.Dermatology practical & conceptual · 2024Article
- Interleukin-38 and Insulin Resistance.Endocrine, metabolic & immune disorders drug targets · 2024Article
- The emerging role of IL-38 in diseases: A comprehensive review.Immunity, inflammation and disease · 2023Review
- IL-38 attenuates myocardial ischemia-reperfusion injury by inhibiting macrophage inflammation.Immunity, inflammation and disease · 2023Article
- Exploratory analysis of interleukin-38 in hospitalized COVID-19 patients.Immunity, inflammation and disease · 2022Article
- Clinical relevance and therapeutic potential of IL-38 in immune and non-immune-related disordersEuropean cytokine network · 2022Review
- Effects of IL-38 on Macrophages and Myocardial Ischemic Injury.Frontiers in immunology · 2022Review
- Circulating interleukin-38 concentrations in healthy adults.Frontiers in immunology · 2022Article
- Interleukin-1 in Coronary Artery Disease.Current topics in medicinal chemistry · 2022Article
- Prognostic value of interleukin-34 and interleukin-38 in patients with newly diagnosed atrial fibrillation.Frontiers in cardiovascular medicine · 2022Article
- Neutralization of interleukin-38 exacerbates coxsackievirus B3-induced acute myocarditis in mice.Virology journal · 2021Article
- Reduced concentrations of the B cell cytokine interleukin 38 are associated with cardiovascular disease risk in overweight subjects.European journal of immunology · 2021Article
- The Role of IL-37 and IL-38 in Obstetrics Abnormalities.Frontiers in medicine · 2021Review
- Interleukin-36 Cytokine/Receptor Signaling: A New Target for Tissue Fibrosis.International journal of molecular sciences · 2020Review
- Interleukin-38 alleviates cardiac remodelling after myocardial infarction.Journal of cellular and molecular medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveRecent studies suggest that IL-38 is associated with autoimmune diseases. Furthermore, IL-38 is expressed in human atheromatous plaque. However, the plasma levels of IL-38 in patients with ST-segment elevation myocardial infarction (STEMI) have not yet to be investigated.
methodsOn admission, at 24 h, at 48 h, and at 7 days, plasma IL-38, C-reactive protein (CRP), cardiac troponin I (cTNI), and N-terminal of the prohormone brain natriuretic peptide (NT-proBNP) levels were measured and IL-38 gene in peripheral blood mononuclear cells (PBMCs) was detected in STEMI patients.
resultsThe results showed that plasma IL-38 levels and IL-38 gene expression in PBMCs were significantly increased in STEMI patients compared with control group and were time dependent, peaked at 24 h. In addition, plasma IL-38 levels were dramatically reduced in patients with reperfusion treatment compared with control group. Similar results were also demonstrated with CRP, cTNI, and NT-proBNP levels. Furthermore, IL-38 levels were found to be positively correlated with CRP, cTNI, and NT-proBNP and be weakly negatively correlated with left ventricular ejection fraction (LVEF) in STEMI patients.
conclusionsThe results indicate that circulating IL-38 is a potentially novel biomarker for patients with STEMI and IL-38 might be a new target for MI study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.